Follow-up Study of French Patients with Cutaneous Squamous Cell Carcinoma Receiving Systemic Treatment

What this Trial Is About

Researchers are studying patients with advanced cutaneous squamous cell carcinoma cSCC, a skin cancer with rising incidence and evolving treatment options. The study aims to describe how systemic therapies are used long-term in real-life settings for patients receiving treatments as curative, adjuvant, or neoadjuvant. This observational study collects data to better understand patient characteristics, treatment use, effectiveness, and safety. The study involves collecting information on patients starting first-line systemic therapy for cSCC from January 2020 onward. It includes both a retrospective phase and a prospective phase, gathering data from about 30 centers in France. Treatments studied include systemic drug therapies given with different intentions such as curative, adjuvant, or neoadjuvant. There is no intervention or randomization the study observes real-world treatment practices and changes over time. Participants are followed long term, with an average follow-up of 5 years to monitor treatment frequency, duration, and outcomes like response rates and survival. Researchers collect baseline patient data at diagnosis and track effectiveness and safety of therapies over time. The study also aims to identify new factors that predict treatment response or side effects. Data collection includes clinical characteristics and treatment details, contributing to a national database for cSCC management.

Follow-up of a French National Cohort of Patients With Cutaneous Squamous Cell Carcinoma Requiring Systemic Treatment.